Zoetis could climb 25%, Barron's says Zoetis (ZTS) isn't subject to the same patent expiration cliff as Pfizer (PFE) and earnings should rise 13% over the next few years, Barron's says in its "Weekday Trader" column. Shares could climb 25%, the paper adds. Reference Link
News For ZTS From The Last 14 Days
Check below for free stories on ZTS the last two weeks.